PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study

PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study

Zhaoqian He,1– 3,* Hua Chen,1– 3,* Chen Liang,1– 3,* Xiang Tang,1– 3 Lingmin Jiang,1– 3 Feihu Xie,1– 3 Qi Liu,1– 3 Yun Zheng1– 3 1Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China; 2Collaborative Innova...

Full description

Saved in:
Bibliographic Details
Main Authors: He Z, Chen H, Liang C, Tang X, Jiang L, Xie F, Liu Q, Zheng Y
Format: Article
Language:English
Published: Dove Medical Press 2025-01-01
Series:ImmunoTargets and Therapy
Subjects:
hepatocellular carcinoma
immunotherapy
hepatic arterial infusion chemotherapy
propensity score matching
real-world study.
Online Access:https://www.dovepress.com/pdl1-inhibitors-plus-lenvatinib-vs-atezolizumab-plus-bevacizumab-combi-peer-reviewed-fulltext-article-ITT
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/pdl1-inhibitors-plus-lenvatinib-vs-atezolizumab-plus-bevacizumab-combi-peer-reviewed-fulltext-article-ITT

Similar Items